Davis's Drug Guide
pembrolizumab
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Genetic Implications:
Pronunciation:
pem-broe-li-zoo-mab
To hear audio pronunciation of this topic, purchase a subscription or log in.Trade Name(s)
- Keytruda
Ther. Class.
Pharm. Class.
monoclonal antibodies
programmed death-1 inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., and Cynthia A. Sanoski. "Pembrolizumab." Davis's Drug Guide, 20th ed., F.A. Davis Company, 2026. Anesthesia Central, anesth.unboundmedicine.com/anesthesia/view/Davis-Drug-Guide/110182/7/pembrolizumab.
Vallerand AHA, Sanoski CAC. Pembrolizumab. Davis's Drug Guide. F.A. Davis Company; 2026. https://anesth.unboundmedicine.com/anesthesia/view/Davis-Drug-Guide/110182/7/pembrolizumab. Accessed June 25, 2026.
Vallerand, A. H., & Sanoski, C. A. (2026). Pembrolizumab. In Davis's Drug Guide (20th ed.). F.A. Davis Company. https://anesth.unboundmedicine.com/anesthesia/view/Davis-Drug-Guide/110182/7/pembrolizumab
Vallerand AHA, Sanoski CAC. Pembrolizumab [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2026. [cited 2026 June 25]. Available from: https://anesth.unboundmedicine.com/anesthesia/view/Davis-Drug-Guide/110182/7/pembrolizumab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - pembrolizumab
ID - 110182
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
BT - Davis's Drug Guide
UR - https://anesth.unboundmedicine.com/anesthesia/view/Davis-Drug-Guide/110182/7/pembrolizumab
PB - F.A. Davis Company
ET - 20
DB - Anesthesia Central
DP - Unbound Medicine
ER -
